![1]()
News
CDC warns against misuse of opioid-prescribing guideline
April 24, 2019
Officials at the Centers for Disease Control and Prevention are advising against misapplication of the agency’s guideline on opioid prescribing.
News
In pain treatment, racial bias common among physician trainees
April 24, 2019
MILWAUKEE – Most residents and fellows who demonstrated racial bias did not report that race factored into treatment decisions.
![1]()
News
FDA approves generic naloxone spray for opioid overdose treatment
April 19, 2019
The agency said the naloxone nasal spray does not need assembly and can be used by anyone, regardless of medical training.
![1]()
News
FDA to expand opioid labeling with instructions on proper tapering
April 10, 2019
The label changes are intended to be used when both the clinician and patient have agreed to reduce the opioid dosage.
![1]()
News
Ticagrelor reversal agent looks promising
March 28, 2019
NEW ORLEANS – Ticagrelor’s antiplatelet effect was squelched within 5 minutes.
![1]()
News
Report calls for focus on ‘subpopulations’ to fight opioid epidemic
March 27, 2019
“Methadone, buprenorphine, and extended-release naltrexone ... save lives” but most people with OUD get no treatment, new report says.
![1]()
News
Better communication with pharmacists can improve postop pain control
March 27, 2019
A pharmacist advises surgeons to make sure to adjust medications based on preoperative or intraoperative doses to avoid endangering patients by inadvertently doubling up on doses.
![1]()
News
Surge of gabapentinoids for pain lacks supporting evidence
March 25, 2019
Review of 54 papers for gabapentin and 30 for pregabalin finds little evidence for effective pain control in off-label uses.
News
Intensive blood pressure lowering may not reduce risk of recurrent stroke
March 20, 2019
HONOLULU – Intensive treatment significantly reduces blood pressure, compared with standard treatment, and is equally safe.
![1]()
News
Andexanet alfa effectively reverses factor Xa inhibition
March 18, 2019
HONOLULU – The drug establishes good or excellent hemostasis in 82% of patients with acute major bleeding associated with factor Xa inhibition.
